Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Victory Pharma Completes Acquisition of Assets of MiddleBrook Pharmaceuticals

By Pharmaceutical Processing | August 3, 2010

Victory Pharma, Inc. has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals, Inc.

Through the acquisition, Victory Pharma has expanded its product portfolio with the addition of anti-infective products MOXATAG and KEFLEX as well as the PULSYS drug delivery technology platform. The product additions complement Victory’s current products, such as NAPRELAN, which the company markets to primary care and specialist physicians.

“This acquisition reflects our strategy of leveraging our existing commercial infrastructure to expand our portfolio of marketed products,” said Matt Heck, president and chief executive officer of Victory Pharma. “The addition of these products balances our portfolio nicely, as NAPRELAN’s highest period of utilization is in the spring and summer, while MOXATAG’s utilization peaks during the flu season. And we believe MOXATAG will substantially benefit from our management team’s prior, successful experience marketing anti-infective products.” MOXATAG is the only FDA-approved, once-daily formulation of amoxicillin, and is indicated for the treatment of tonsillitis and/or pharyngitis. MOXATAG utilizes PULSYS technology to deliver drug at set intervals over a 24 hour period, whereas other amoxicillin products require multiple times daily dosing. Reduced dosing frequency can improve therapy compliance, which is potentially important given patient non-compliance is widely-recognized as the primary reason for antibiotic therapy failure, and non-compliant patients have been shown to have a 175 percent greater chance of infection recurrence.    

 

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE